Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain pacemaker tested in older Parkinson's patients

NCT ID NCT03128567

Disease control Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This trial investigates whether deep brain stimulation of the subthalamic nucleus can improve quality of life for people aged 70 and older with Parkinson's disease. Participants are randomly assigned to receive the stimulation or standard care. The study measures changes in motor symptoms, cognitive function, and overall well-being using a Parkinson's-specific quality-of-life questionnaire.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
deep brain stimulation of the subthalamic nucleus (a device that sends electrical pulses to a specific brain area)
What this could lead to
If successful, this could show that deep brain stimulation is a safe and effective option for older adults with Parkinson's, improving their daily life and mobility.
What could go wrong
This is a small, early-stage trial with only 10 participants, so results may not apply to everyone. There is a risk of side effects like cognitive decline or falls in older patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

10 people

The number who actually took part.

Started

Nov 2017

Finished

Feb 2020

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Parkinson's disease

Ages

69 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Parkinson's disease * disease duration \> 5 years * levodopa related motor complications * dopasensitivity \> 50% * signed informed written consent * medical social insurance Exclusion Criteria: * dementia * contra-indication to neurosurgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • CHU Charles Nicolle

    Rouen, 76000, France

  • Centre d'Investigation Clinique - CIC 1436. CHU PURPAN. Hôpital Pierre Paul Riquet

    Toulouse, 31059 Toulouse Cedex 9, France

  • Département des maladies du Système Nerveux, Hôpital Pitié-Salpétrière

    Paris, 75013, France

  • Hôpital Neurologique Pierre Wertheimer, Service de Neurologie

    Lyon, 69677 Bron cedex, France

  • Hôpital Roger Salengro - CHRU de Lille Service de Neurologie et Pathologie du Mouvement

    Lille, 59037 Lille Cedex, France

  • Service d'EFSN, Hôpital Pellegrin

    Bordeaux, 33076, France

  • Service de Neurologie, Pôle Neurosciences, CHU de Poitiers

    Poitiers, 86021 Poitiers cedex, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.